Search

Displaying results 951 - 960 of 10000 in total
  1. Drug

    Exenatide

    go.drugbank.com/drugs/DB01276
    ApprovedInvestigational

    Exenatide is a glucagon-like peptide-1 (GLP-1) analog[L42690].

    Products: BYETTA 10 µG/40 µL SC KULLANIMA HAZIR DOLU ENJEKSİYON KALEMI ICINDE COZELTI, 2.4 ML (60 DOZ), BYDUREON 2 mg powder and solvent for prolonged-release suspension for injection
  2. Drug

    Lenvatinib

    go.drugbank.com/drugs/DB09078
    ApprovedInvestigational

    In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers … Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsProducts: LENVIMA HARD CAPSULES 10 MG, Lenvima 4 mg Hard Capsules
  3. Drug

    Teicoplanin

    go.drugbank.com/drugs/DB06149
    ApprovedInvestigationalWithdrawn

    Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). … All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.

    Products: Teicoplanin Accord 100 mg Pulver zur Herstellung einer Injektionslösung, Teicoplanin Mylan 100 mg Pulver zur Herstellung einer Injektions-/Infusionslösung oder einer Lösung zum Einnehmen
  4. Drug

    Starch, corn

    go.drugbank.com/drugs/DB11599
    ApprovedInvestigationalNutraceutical

    Corn starch may be added in some food products as a thickening agent or anti-caking agent, and is sometimes found in topical drugs as a skin protectant. … Starch is any of a group of polysaccharides of the general formula (C6-H10-O5)n, composed of a long-chain polymer of glucose in the form of amylose and amylopectin.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: Starch 1500, Starch 1500 pregelatinized
  5. Drug

    Tenapanor

    go.drugbank.com/drugs/DB11761
    ApprovedInvestigational

    Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). … A185492] As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first and currently only medication within its class[A185489,A185492,A185495] and therefore exists as a

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: XPHOZAH 10 mg, XPHOZAH 20 mg
  6. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Enhertu 100 mg IV İnfüzyonluk Çözelti Hazırlamada Kullanılacak Konsantre İçin Toz, 1 ADET
  7. Drug

    APG-157

    go.drugbank.com/drugs/DB18683
    InvestigationalNutraceutical

    APG-157 consists of zinflavonoids being investigated for the treatment of cancers.

  8. Drug

    Moexipril

    go.drugbank.com/drugs/DB00691
    ApprovedInvestigational

    Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension).

    Mixtures: UNIRETIC 15 MG/ 25 MG FILM KAPLI TABLET, 30 ADET, UNIRETIC 7,5 MG/ 12.5 MG FILM KAPLI TABLET, 30 ADETProducts: UNIVASC 15 MG FILM TABLET, 20 ADET, UNIVASC 7,5 MG FILM TABLET, 20 ADET
  9. Drug

    H-151

    go.drugbank.com/drugs/DB29149
    Experimental

    H-151 is an inhibitor of the stimulator of interferon genes (STING) protein.

    Synonyms: H-151
  10. Drug

    Selumetinib

    go.drugbank.com/drugs/DB11689
    ApprovedInvestigational

    [A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved. … [A193608] It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: Koselugo Hard Capsules 10 mg, Koselugo Hard Capsules 25 mg